In our previous study, we demonstrated the effectiveness of the VDAC1-based peptides, Tf-D-LP4, in treating steatosis and NASH as induced in STZ/HFD-32 fed mice [23]. This evidence concerns the gene VDAC1 and metabolic dysfunction-associated steatohepatitis.